Insider Transactions in Q4 2021 at Entrada Therapeutics, Inc. (TRDA)
Insider Transaction List (Q4 2021)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 29
2021
|
Nerissa Kreher Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,200
+50.0%
|
$10,400
$2.1 P/Share
|
Nov 02
2021
|
Kush Parmar Director |
BUY
Open market or private purchase
|
Indirect |
250,000
+18.09%
|
$5,000,000
$20.0 P/Share
|
Nov 02
2021
|
Kush Parmar Director |
BUY
Conversion of derivative security
|
Indirect |
3,827,224
+32.12%
|
-
|
Nov 02
2021
|
Todd Foley Director |
BUY
Open market or private purchase
|
Indirect |
100,000
+2.21%
|
$2,000,000
$20.0 P/Share
|
Nov 02
2021
|
Todd Foley Director |
BUY
Conversion of derivative security
|
Indirect |
4,325,784
+30.26%
|
-
|
Nov 02
2021
|
Mpm Bio Ventures 2014, L.P. |
BUY
Open market or private purchase
|
Indirect |
100,000
+2.21%
|
$2,000,000
$20.0 P/Share
|
Nov 02
2021
|
Mpm Bio Ventures 2014, L.P. |
BUY
Conversion of derivative security
|
Indirect |
4,325,784
+30.26%
|
-
|
Nov 02
2021
|
Mpm Bioventures 2018, L.P. |
BUY
Open market or private purchase
|
Indirect |
100,000
+2.21%
|
$2,000,000
$20.0 P/Share
|
Nov 02
2021
|
Mpm Bioventures 2018, L.P. |
BUY
Conversion of derivative security
|
Indirect |
4,325,784
+30.26%
|
-
|
Nov 02
2021
|
Redmile Group, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,000,000
+33.85%
|
$20,000,000
$20.0 P/Share
|
Nov 02
2021
|
Redmile Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
954,420
+50.0%
|
-
|
Nov 02
2021
|
5 Am Ventures V, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
250,000
+18.09%
|
$5,000,000
$20.0 P/Share
|
Nov 02
2021
|
5 Am Ventures V, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,827,224
+32.12%
|
-
|
Nov 02
2021
|
Roche Holding LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,813,525
+30.08%
|
-
|